Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain

BOSTON--(BUSINESS WIRE)--Jul. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionectomy surgery with the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials